Results 21 to 30 of about 2,243,647 (283)
CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1 [PDF]
Advanced SciencePancreatic ductal adenocarcinoma (PDAC) is a fatal cancer with poor prognosis. COP9 signalosome subunit 6 (CSN6), a key regulator of different E3 ubiquitin ligases, plays oncogenic roles in various cancers.
Yijing Zhang +14 more
doaj +2 more sources
PLoS ONEGemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh +6 more
doaj +2 more sources
Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma. [PDF]
Oncol ResCholangiocarcinoma (CCA) is an aggressive cancer originating from bile duct epithelium. Surgical resection remains the primary curative treatment for CCA. However, most CCA patients are diagnosed at an advanced stage, which limits the applicability of surgical resection. Gemcitabine is widely used as a first-line chemotherapeutic agent for unresectable
Kidoikhammouan S +3 more
europepmc +3 more sources
CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. [PDF]
Clin Transl MedLINC01503 encoded a 91‐amino acid protein named 1503‒91aa, which enhanced carnitine palmitoyl transferase 1A (CPT1A) activity and regulated fatty acid oxidation (FAO) by competitively binding to malonyl‐CoA. Meanwhile, we found a positive feedback loop whereby CPT1A acts as a succinyltransferase to stabilise CTCF (a transcription factor driving ...
Fang DL +8 more
europepmc +2 more sources
Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]
Research in Oncology, 2021 Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei +4 more
doaj +1 more source
Review of molecular mechanisms underlying gemcitabine resistance in pancreatic cancer [PDF]
The Journal of Qazvin University of Medical Sciences, 2017 Pancreatic cancer is one the most malignant cancers in human. A great percentage of patients die annually due to lack of early detection as well as efficient treatment strategies. Only five-year survival rate is still only seen in 5% of patients.
A. Rajabpour +2 more
doaj +1 more source
Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma. [PDF]
Cancers (Basel)Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings.
Yamashita T +5 more
europepmc +2 more sources
Molecular Cancer, 2022 Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu +12 more
doaj +1 more source
Cell Death and Disease, 2021 The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun +5 more
doaj +1 more source
Biomedicines, 2022 Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance.
C. Arnold Spek +2 more
doaj +1 more source